HORIZON PHARMA PLC's gross profit margin for the second quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. HORIZON PHARMA PLC is extremely liquid. Currently, the Quick Ratio is 2.92 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 1,454.44% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||172.82||66.06|
|Net Income ($mil)||31.81||-27.77|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||667.66||129.59|
|Total Assets ($mil)||2942.69||328.36|
|Total Debt ($mil)||1136.9||114.79|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||93.17||90.4|
|Return on Assets||-0.58||-104.27|
|Return on Equity||-1.38||-424.46|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||158.35||74.29|
|Div / share||0.0||0.0|
|Book value / share||7.92||1.09|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3790302.0||3900847.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 2.57 indicates valuation on par with the S&P 500 average of 2.58 and a significant discount versus the industry average of 5.55. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, HORIZON PHARMA PLC proves to trade at a discount to investment alternatives within the industry.
|HZNP NM||Peers 29.88||HZNP NM||Peers 19.68|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
HZNP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
HZNP's P/CF is negative making the measure meaningless.
|HZNP 11.50||Peers 16.41||HZNP NA||Peers 0.92|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
HZNP is trading at a valuation on par with its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|HZNP 2.57||Peers 5.55||HZNP 95.88||Peers -115.48|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
HZNP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
HZNP is expected to have an earnings growth rate that significantly exceeds its peers.
|HZNP 6.93||Peers 11.66||HZNP 170.02||Peers 6.83|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
HZNP is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
HZNP has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas